Cardiol Therapeutics (TSE:CRDL) has released an update.
Cardiol Therapeutics Inc. has received consent from Borden Ladner Gervais LLP for the use of their name and opinions in the prospectus supplement dated July 16, 2024. This consent is related to the issuance of common shares upon the exercise of warrants as part of their U.S. Registration Statement. The law firm, however, does not consider themselves as being in the category of persons requiring consent under the Securities Act of 1933.
For further insights into TSE:CRDL stock, check out TipRanks’ Stock Analysis page.
